KDM4A and neoplasm: The above results suggest that in in vivo experiments, knocking down KDM4A-AS1 alone can significantly inhibit tumor growth, while the combined application of enzalutamide can reduce the tumor volume and restore C4-2-EnzR sensitivity to enzalutamide.